Compare RWT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | ESPR |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | 351 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.5M | 731.9M |
| IPO Year | N/A | 2013 |
| Metric | RWT | ESPR |
|---|---|---|
| Price | $5.26 | $3.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $6.82 | ★ $8.75 |
| AVG Volume (30 Days) | 1.2M | ★ 16.6M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.83% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | $26.59 | N/A |
| Revenue Next Year | $22.21 | $12.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $5.00 | $0.76 |
| 52 Week High | $6.97 | $4.18 |
| Indicator | RWT | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 70.78 |
| Support Level | $5.04 | $2.37 |
| Resistance Level | $5.39 | $3.18 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.05 | 0.11 |
| Stochastic Oscillator | 4.00 | 96.01 |
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.